StocksMedium•6 November 2026•
1 min read
Immunic Stock Under Pressure as CALLIPER Trial Misses Primary Brain-Volume Endpoint
Key Facts
1Immunic announced that its CALLIPER trial missed its primary brain-volume endpoint.
2The trial demonstrated positive exploratory signals, supporting plans for a Phase 3 trial in progressive multiple sclerosis.
Immunic announced that its CALLIPER clinical trial missed its primary brain-volume endpoint. Benzinga reported that the trial failed to meet the statistically significant threshold for its primary objective in progressive multiple sclerosis, despite identifying secondary benefits.
The trial demonstrated positive exploratory signals that support the company's plans to transition to a Phase 3 clinical trial in the first half of 2027. Shares of Immunic, trading under the ticker IMUX, closed at $7.32 on November 5, 2026, after seeing a session range between $7.21 and $8.07.